RxDoctor Payments Data

Richard Blansky, MD

Gastroenterology · Binghamton, NYNPI 1790725778

Payments from drug & device makers

$1,157in general payments, 2019–2025

Across 61 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260
  • Johnson & Johnson$141
  • Pfizer$128
  • Boston Scientific$119
  • Medical Device Business Services, Inc.$109
  • Gilead$77
  • plus $324 from 9 others

What the payments were for

  • Food & beverage$1,10395%
  • Education$545%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,157 in reported general payments places this provider in the 35th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$48,521
Medicare patients
255
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$389,359
XifaxanRifaximin28$117,761
CreonLipase/Protease/Amylase25$66,277
Mesalamine37$43,527
Mesalamine ErMesalamine40$23,132
LinzessLinaclotide27$20,369
Budesonide DrBudesonide28$7,470
Ursodiol36$7,122
Balsalazide Disodium27$6,312
Budesonide EcBudesonide18$5,190
Mercaptopurine22$3,093
Colestipol Hcl42$2,895
Sulfasalazine32$1,468
Famotidine125$1,369
Pantoprazole Sodium145$1,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$141$389,35919 claims
AbbVieCreon, Linzess$260$86,64652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →